Mesoblast’s Revascor gets FDA nod, but shares dip
Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy designation to its Revascor (rexlemestrocel-L) drug for children with hypoplastic left heart syndrome (HLHS). This builds on earlier FDA designations of Rare Pediatric Disease (RPD) and Orphan-Drug (OD) status for the therapy. Mesoblast develops allogeneic (off-the-shelf) cellular medicines […]
Mesoblast’s Revascor gets FDA nod, but shares dip Read More »